Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Resumes Mirum Pharmaceuticals (MIRM) at Buy, PT $89, 'stands out in what remains a discerning biotech tape'
August 11, 2025 5:48 AM EDTStifel analyst James Condulis resumes coverage on Mirum Pharmaceuticals (NASDAQ: MIRM) with a Buy rating and a price target of $89.00.
The analyst comments "We're resuming coverage of Mirum with a Buy rating and an $89 target price. Mirum is a unique rare disease biotech with: (1) a cash-flow... More
